Sensei biotherapeutics to participate in citi's 2022 virtual immuno-oncology summit

Boston, feb. 11, 2022 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in citi's 2022 immuno-oncology summit.
SNSE Ratings Summary
SNSE Quant Ranking